Veracyte, Inc. — Q1 2024 Form 10-Q
Business context and reporting period. Veracyte is a global cancer diagnostics company offering tests including Afirma, Decipher, and Prosigna. This unaudited filing covers the three months ended March 31, 2024, compared with Q1 2023. In February 2024, Veracyte acquired C2i, expanding into minimal residual disease (MRD) detection.
Financial results and liquidity
| Metric | Q1 2024 | Q1 2023 / comparison |
|---|---|---|
| Total revenue | $96.8 million | $82.4 million; up 17% |
| Testing revenue | $90.3 million | $72.4 million; up 25% |
| Product revenue | $3.5 million | $3.9 million; down 9% |
| Biopharmaceutical and other revenue | $3.0 million | $6.1 million; down 51% |
| Gross profit and margin | Approximately $65.4 million; 67.5% | Approximately $56.2 million; 68.2% |
| Operating loss | $4.7 million | $10.5 million |
| Net loss | $1.9 million; $0.02 per share | $8.1 million; $0.11 per share |
| Operating cash flow | $(9.0) million | $(2.2) million |
| Cash and cash equivalents at quarter-end | $209.2 million | $216.5 million at December 31, 2023 |
Diagnostic tests reported increased 20% to 30,969; total test volume, including product tests sold, increased 16% to 33,424. Testing revenue growth reflected 20% higher diagnostic volume and a 4% increase in average selling price across Afirma and Decipher. Gross margin edged down despite higher revenue. Operating expenses rose 9% to $101.5 million, including higher R&D and G&A, partly offset by lower selling and marketing expenses.
Current assets were $290.4 million and current liabilities $58.1 million. The balance sheet reports no borrowings; liabilities primarily include leases and acquisition-related contingent consideration. Total operating lease liabilities were $14.0 million. Cash, cash equivalents, and restricted cash totaled $210.3 million. Operating cash use increased year over year, principally reflecting working-capital outflows, including higher receivables and lower accrued liabilities and deferred revenue.
Material changes, outlook, and risks
- C2i acquisition: Veracyte acquired C2i for preliminary consideration of approximately $100.2 million, including about $73.3 million in stock and contingent consideration. The acquisition added approximately $56.0 million of goodwill and $31.5 million of intangible assets. C2i contributed no revenue and a $4.2 million operating loss from the acquisition date through quarter-end. Purchase-price allocation remains preliminary. Veracyte may owe up to $25 million in additional milestone consideration, payable in cash or shares at its election.
- Outlook and liquidity: Management expects additional losses for the remainder of 2024 and potentially future years, but believes existing cash and cash flows from revenue will meet anticipated cash needs for at least 12 months from the filing date. The filing provides no specific full-year revenue or test-volume guidance.
- Revenue and reimbursement exposure: Medicare represented 31% of Q1 revenue; UnitedHealthcare represented 9%. Reimbursement decisions, denials, appeals, collection timing, and changes to payer coverage or rates may affect revenue and cash flow. Q1 testing revenue included $3.0 million from collections exceeding prior estimates on tests reported in earlier years.
- Development and operating risks: Management expects continued investment in R&D, including clinical evidence for Percepta Nasal Swab and urology tests, IVD-platform development, and MRD programs. Biopharmaceutical revenue declined amid customer project reductions and industry spending constraints. Critical reagents, equipment, and services include single-source suppliers; NanoString’s February 2024 Chapter 11 filing could affect supply, service, or license obligations.
- Regulatory and integration risks: The filing discusses the FDA’s April 29, 2024 final LDT rule and potential future compliance requirements. Veracyte believes certain existing tests will continue to benefit from enforcement discretion, but regulatory changes could affect current or future tests. The company is integrating C2i and notes potential operational disruption related to the Middle East conflict, as well as energy and supply risks affecting its Marseille operations.
- Other items: Q1 included $4.9 million of C2i transaction costs in G&A and $1.3 million of C2i severance and retention charges. Management reported disclosure controls were effective at the reasonable-assurance level; C2i is being incorporated into internal-control evaluation.
Important facts for investors to verify
- Whether diagnostic test growth and average selling prices persist, and how the higher cost of testing affects margins and cash generation.
- Collections on accounts receivable and the sustainability of revenue estimates, including adjustments related to prior-period tests.
- Progress integrating C2i, achieving its milestones, and any resulting contingent payments, dilution, or impairment risk.
- Developments in payer coverage and reimbursement, particularly Medicare policies and commercial payer contracts.
- Effects of the FDA LDT rule, NanoString’s bankruptcy, single-source supply dependencies, and geopolitical or energy disruptions on testing and product delivery.
- Cash use relative to management’s 12-month liquidity assessment; the company reports continued expected losses and no specific full-year guidance.